Compare PROF & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.4M | 203.7M |
| IPO Year | N/A | N/A |
| Metric | PROF | GALT |
|---|---|---|
| Price | $7.88 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $12.00 | $8.50 |
| AVG Volume (30 Days) | 231.5K | ★ 415.7K |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,297,000.00 | N/A |
| Revenue This Year | $64.23 | N/A |
| Revenue Next Year | $113.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 67.94 | N/A |
| 52 Week Low | $3.76 | $1.12 |
| 52 Week High | $8.95 | $7.13 |
| Indicator | PROF | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 37.73 |
| Support Level | $7.22 | $2.76 |
| Resistance Level | $8.15 | $3.56 |
| Average True Range (ATR) | 0.56 | 0.22 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 37.86 | 31.25 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.